alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 51–75 of 444 studies · free to read (page 3 of 18) · 27,780 in the whole library · How the 0–100 score works

Download bibliography of these 444 studies, in this order: BibTeX (.bib) · RIS (.ris)

Showing 444 studies tagged randomized — clear

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,259 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial

✓ Peer-reviewed alzhub usefulness score 74 out of 100. JAMA 2023-08-01

Among 1736 randomized participants (mean age, 73.0 years; 996 [57.4%] women; 1182 [68.1%] with low/medium tau pathology and 552 [31.8%] with high tau pathology), 1320 (76%) completed the trial. 3 key findings →

Design: clinical trial Participants: 860 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)

✓ Peer-reviewed alzhub usefulness score 74 out of 100. Archives of medical science : AMS 2011-02-01

The primary planned analyses did not show a significant treatment effect, but were confounded by unexplained variance. 5 key findings →

Design: randomized controlled trial Participants: 1,052 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 74 out of 100. Neurology 2018-04-25

Although prespecified criteria for testing treatment effects were not met, these data suggest a potential treatment effect in patients with mild AD treated with high-dose crenezumab. 4 key findings →

Design: clinical trial Participants: 184 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 74 out of 100. Neurology 2019-04-05

In cognitively intact individuals at risk, sustained treatment with naproxen sodium 220 mg twice daily increases frequency of adverse health effects but does not reduce apparent progression of presymptomatic AD. 4 key findings →

Participants: 195 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia

✓ Peer-reviewed alzhub usefulness score 74 out of 100. Alzheimer's research & therapy 2021-03-17

A significant drug-placebo difference on the ADAS-Cog12 favoring GV-971 was present at each measurement time point, measurable at the week 4 visit and continuing throughout the trial. 3 key findings →

Design: clinical trial Participants: 818 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE)

✓ Peer-reviewed alzhub usefulness score 74 out of 100. JAMA neurology 2017-05-01

In both phases, men were encouraged to visit their physician if the screen results indicated possible cognitive impairment. 3 key findings →

Design: cohort study Participants: 7,540 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment

✓ Peer-reviewed alzhub usefulness score 74 out of 100. Proceedings of the National Academy of Sciences of the United States of America 2013-05-20

Is it possible to prevent atrophy of key brain regions related to cognitive decline and Alzheimer's disease (AD)? 3 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease

✓ Peer-reviewed alzhub usefulness score 74 out of 100. The Cochrane database of systematic reviews 2012-03-14

Previous Cochrane reviews have considered the use of cholinesterase inhibitors in both Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB). 4 key findings →

Participants: 1,236 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial

✓ Peer-reviewed alzhub usefulness score 74 out of 100. PLoS medicine 2018-09-24

This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine. 4 key findings →

Participants: 577 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 74 out of 100. Alzheimer's research & therapy 2021-05-27

At randomization, the mean age is 72, 50% female, 77% with CDR-global score 0.5, and mean MMSE score 23.8. 5 key findings →

Design: clinical trial Participants: 464 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Extended results of the Alzheimer's disease anti-inflammatory prevention trial

✓ Peer-reviewed alzhub usefulness score 73 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2011-07-01

These data suggest a revision of the original ADAPT hypothesis that NSAIDs reduce AD risk, as follows: NSAIDs have an adverse effect in later stages of AD pathogenesis, whereas asymptomatic individuals treated with conventional NSAIDs such as naproxen experience reduced AD incidence, but only after 2 to 3 years. 5 key findings →

Participants: 54 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial

✓ Peer-reviewed alzhub usefulness score 73 out of 100. JAMA 2015-08-01

Among older persons with AMD, oral supplementation with LCPUFAs or lutein/zeaxanthin had no statistically significant effect on cognitive function. 5 key findings →

Participants: 89 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Effect of Cholinesterase Inhibitors on Mortality in Patients With Dementia: A Systematic Review of Randomized and Nonrandomized Trials

✓ Peer-reviewed alzhub usefulness score 73 out of 100. Neurology 2022-11-14

We included randomized controlled trials (RCTs) and nonrandomized controlled studies at lower risk of bias comparing ChEI treatment with placebo or usual treatment, for 6 months or longer, in patients with dementia of any type. 5 key findings →

Design: systematic review Participants: 79,153 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 72 out of 100. Neurology 2024-02-22

In participants with early symptomatic AD, zagotenemab failed to achieve significant slowing of clinical disease progression compared with placebo. 5 key findings →

Design: clinical trial Participants: 360 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial

✓ Peer-reviewed alzhub usefulness score 72 out of 100. Neurology 2015-05-01

This study showed that subcutaneous etanercept (50 mg/wk) was well tolerated in this small group of patients with Alzheimer disease dementia, but a larger more heterogeneous group needs to be tested before recommending its use for broader groups of patients. 4 key findings →

Participants: 20 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Safety, Tolerability, and Feasibility of Young Plasma Infusion in the Plasma for Alzheimer Symptom Amelioration Study: A Randomized Clinical Trial

✓ Peer-reviewed alzhub usefulness score 72 out of 100. JAMA neurology 2019-01-01

There was no difference in the age (mean [SD], 74.17 [7.96] years), sex (12 women [67%]), or baseline Mini-Mental State Examination score (mean [SD], 19.39 [3.24]) between the crossover (n = 9) and open-label groups (n = 9). 3 key findings →

Design: open-label trial Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed